---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015549"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T03:01:28.514862+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma Q2 net loss widens to $13.9M; cash runway into 2025

## Summary
- Net loss of $13.9M ($0.55 per share) vs $10.7M ($0.43) in Q2 2021.
- Cash and equivalents $139.8M as of June 30, down from $166.0M at Dec 31, 2021; expected to fund operations into 2025.
- R&D expenses $8.7M (up from $6.0M); G&A $5.4M (up from $4.9M).
- TERN-701 Phase 1 CML trial initiated in China; TERN-601 IND-enabling on track for Phase 1 obesity trial in 2023.
- TERN-501 Phase 2a DUET NASH trial initiated; top-line data expected H2 2023.

## SEC filing metadata
- accession: 0000950170-22-015549
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/0000950170-22-015549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/tern-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015549
- JSON: https://secwatch.observer/filing/0000950170-22-015549.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.